In the PIONEER program, cholelithiasis occurred more often in the semaglutide-treated group (0.6% versus 0.1% with placebo), while the risk of cholecystitis was similar (data derived from the summary of product characteristics (SmPC) (87), as the manuscripts did not describe these data)
Lund A, Knop FK, Vilsbll T
What to expect when you taper Because of how long GLP-1s stick around in the body, there are no symptoms due to the sudden stop of the medication, Alkhaddo says
Discomfort often peaks in the morning due to overnight mucosal stasis
GLP-1 agonists slow appetite and help regulate blood sugar by mimicking a natural hormone in the body, called glucagon-like peptide-1, which is released after eating
Do not under any circumstances reuse a needle or pen